A Phase 2a study to evaluate, safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in patients with amyotrophic lateral sclerosis (ALS) A Phase 2a study to evaluate, safety, tolerability, pharmacodynamic markers, and pharmacokinetics of ...
A Phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in patients with familial amyotrophic lateral sclerosis (fALS) and sporadic amyotrophic lateral sclerosis (sALS) A Phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tole ...
Product Name: AP-101 Product Code: AP-101 INN or Proposed INN: Not yet available Other descriptive name: Anti-(misfolded human superoxide dismutase 1) human IgG1m3 monoclonal antibody Product Name: AP-101 Product Code: AP-101 INN or Proposed INN: Not yet available Other descriptive name ...
AL-S Pharma, AG
NULL
Authorised-recruitment may be ongoing or finished
Female: yes Male: yes
63
Phase 2
United States;Canada;Germany;Sweden;Korea, Republic of
A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)
A Multicenter, Open Label, Single-Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS) A Multicenter, Open Label, Single-Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmac ...